Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1674 1699
This examiner grants 56% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17708660 | METHODS FOR TREATING IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNOSUPPRESSION | Final Rejection | Novo Nordisk A/S |
| 18497169 | MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF | Non-Final OA | ImmunityBio, Inc. |
| 18497163 | MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF | Non-Final OA | ImmunityBio, Inc. |
| 18628097 | METHODS OF TREATING NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | Non-Final OA | Novartis AG |
| 18278085 | COMPOSITIONS AND METHODS FOR CARDIOMYOCYTE TRANSPLANTATION | Non-Final OA | UNIVERSITY OF WASHINGTON |
| 17920942 | CD25-TARGETED IL-2 FOR INCREASING CD4 T CELL FORMATION AND TREATMENT OF INFECTIONS | Final Rejection | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. |
| 18246604 | METHODS AND COMPOSITIONS FOR IN SITU IMMUNE PROFILING OF HEART TRANSPLANT BIOPSIES | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17563392 | COMPOSITIONS, COMPRISING IMPROVED IL-12 GENETIC CONSTRUCTS AND VACCINES, IMMUNOTHERAPEUTICS AND METHODS OF USING THE SAME | Final Rejection | The Trustees of the University of Pennsylvania |
| 18828243 | EARLY INTERVENTION METHODS TO PREVENT OR AMELIORATE TOXICITY | Final Rejection | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 17426041 | CHIMERIC CYTOKINE RECEPTORS | Non-Final OA | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18516006 | Therapeutic RNA | Non-Final OA | BioNTech SE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy